procaine may leads to higher total adverse events in "healthy" persons compared with placebo (low certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with adverse events, compared with placebo (low certainty).
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
Summary of findings: cycled showed no clear difference in adverse events: severe adverse events (total) compared with culture‐based antibiotic therapy (moderate certainty).
The intervention showed no clear difference in total serious adverse events Systolic targets (low certainty).
Recombinant human factor VII activated showed no clear difference in serious adverse events by total adverse events compared with placebo (high certainty).
It is very uncertain whether tricyclic antidepressant changes total number of adverse events patient interview compared with control (very low certainty).
Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).
Paracetamol showed no clear difference in total adverse events: number experiencing 24 weeks compared with placebo (high certainty).
The review found no eligible studies for this question.
It is very uncertain whether muscle relaxant changes total Number of Adverse Events ‐ single dose studies compared with control (very low certainty).
It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).
Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty).
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).